StreetAlpha.app
Home › Stocks › XFOR

X4 Pharmaceuticals, Inc (XFOR)

Healthcare
$3.09
▲ +9.19%
LAST CLOSE · NOV 17

X4 Pharmaceuticals develops and sells oral treatments for rare blood diseases, led by XOLREMDI (mavorixafor) for WHIM syndrome. It last closed at $3.09 on Nov 17, up 9.19% on the day.

AI Auto Pilots
Is XFOR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$9.8M
+69.0% vs a year ago
Net income
−$80.5M
−821.6% margin
Gross margin
68.4%
$6.7M gross profit
Operating margin
−820.3%
−$80.4M operating income
Valuation
Market cap
$315.5M
102.1M shares
P/E
–
Price to sales
32.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$185.8M
At Sep 30
Debt
$75.0M
At Sep 30
Shareholder equity
$138.9M
Shares outstanding
102.1M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $2.6M$2.6MFY2024FY2025: $6.5M$6.5MFY2025

From XFOR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated XFOR in the past 90 days.
Average 12-month target
No price targets on XFOR in the past 90 days.
Latest rating changes
Wells FargoInitiated
Jul 10Buy$11
Leerink PartnersInitiated
Jun 2Buy$12
DateFirmActionRatingPrice target
Jul 10Wells FargoInitiatedBuy$11
Jun 2Leerink PartnersInitiatedBuy$12
Loading…

Technical Analysis

XFOR · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 4% below its 20 day and 1% below its 50 day average. It is 22% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 48). The nearest support is the swing low (Oct 29) at $3.05, and the nearest resistance the 50 day average at $3.12.

Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 7.8%/day
Key levels
$4.8352 week high+56.3%
$3.77200 day average+22.0%
$3.60100 day average+16.5%
$3.46Swing high (Nov 9)+12.0%
$3.2020 day average+3.6%
$3.18Pivot R1+2.9%
$3.1250 day average+1.0%
$3.09Last close
$3.05Swing low (Oct 29)−1.3%
$3.01Pivot−2.6%
$2.91Pivot S1−5.8%
$2.4352 week low−21.4%
Indicators
RSI (14)48.23Middle of its rangeNeutral
MACD-0.01Below its signal lineBearish
Stochastic26.5Middle of its rangeNeutral
ADX (14)18.7No clear trend
Williams %R-59.7Oversold below −80, overbought above −20Neutral
CCI (20)-111.3Oversold below −100, overbought above 100Oversold
Rate of change−2.5%Change over 10 sessionsBearish
ATR (14)$0.24Typical daily range, 7.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XFOR

What happened before

See how XFOR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow XFOR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How XFOR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in XFOR in the last 90 days.

Loading…

See today’s whale options flow across the market →

XFOR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲50 buying vs 35 selling
  • ▲Held by funds +2.8 pts
  • ▲Funds holding +8
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9789+9.0%
In funds' top 1035−40.0%
Held by funds106.0%103.2%+2.8 pts
New / increased14 / 3632 / 25−12.3%
Reduced / sold out29 / 612 / 27−10.3%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XFOR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XFOR is in one of them and how their past XFOR trades turned out.

XFOR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XFOR in an article yet. Here's the latest on the wider market.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that develops and sells treatments for rare blood diseases. Its main product, XOLREMDI (mavorixafor), is an oral capsule approved in the United States for WHIM syndrome, a rare immune disorder, and patients can obtain it through a specialty pharmacy. The company is also developing mavorixafor for chronic neutropenia, a rare blood condition, and works with partners to commercialize its products outside the United States.

Headquarters
Boston, MA